Since arriving in Wuhan, the scientific research team led by Academician Chen Wei of the Academy of Military Medical Research has concentrated on emergency research in vaccine development. Yesterday (March 16) 20:18, the research team The recombinant COVID-19 coronavirus vaccine was approved to start clinical trials.
Since arriving in Wuhan on January 26, Academician Chen Wei's team has teamed up with local advantaged enterprises to build on the experience of successful development of Ebola vaccines, and to race against time to carry out pharmaceutical, pharmacodynamic, and pharmacological and toxicological research on recombinant new coronavirus vaccines. Quickly completed the design of the COVID-19 vaccine, the construction of recombinant strains and production under GMP conditions, as well as the safety, effectiveness evaluation and quality review of third-party vaccines. Last night, the COVID-19 vaccine developed by Academician Chen Wei's team passed the clinical research registration review and was approved for clinical trials.
Chen Wei, an academician of the Chinese Academy of Engineering and a researcher at the Military Medical Research Institute of the Academy of Military Sciences, said in an exclusive interview with CCTV reporters from CCTV that in accordance with international standards and domestic regulations, vaccines have been made safe, effective, controllable quality and can be produced on a large scale initial preparation work.
0 Comments